Market Place
Sourcing Support
Ultragenyx & Mereo BioPharma Announce New Pha2 Data from Phase 2/3 Orbit Study
11 Jun 2024 //
GLOBENEWSWIRE
Ultragenyx Completes Enrollment in Ph3 Setrusumab OI Studies ORBIT, COSMIC
30 Apr 2024 //
GLOBENEWSWIRE
Mereo BioPharma Reports Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023
09 Oct 2023 //
GLOBENEWSWIRE
Ultragenyx Announces First Patients Dosed in Ph3 Program Evaluating Setrusumab
06 Jul 2023 //
GLOBENEWSWIRE
Ultragenyx & Mereo Announce Positive Data from Ph2/3 Orbit Study of Setrusumab
05 Jun 2023 //
GLOBENEWSWIRE
Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
09 Sep 2022 //
GLOBENEWSWIRE
Ultragenyx Begins Dosing in Pivotal Phase 2/3 Clinical Study of Setrusumab
20 Apr 2022 //
GLOBENEWSWIRE
Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement
18 Dec 2020 //
GLOBENEWSWIRE
Ultragenyx and Mereo Announce Collaboration and License Agreement
18 Dec 2020 //
GLOBENEWSWIRE
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab
25 Sep 2020 //
GLOBENEWSWIRE
Mereo completes Type B End-of-Phase 2 meeting with US FDA and outlines phase 3
03 Mar 2020 //
PHARMABIZ
Celgene says no to Mereo’s cancer drug etigilimab
22 Jun 2019 //
PM LIVE
Mereo’s shareholders back OncoMed takeover
18 Apr 2019 //
PMLIVE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.